"Viking Therapeutics' Weight-Loss Pill Shows Promising Phase 1 Results, Stocks Soar"
Originally Published 1 year ago — by Yahoo Finance
Viking Therapeutics' stock surged over 25% after reporting positive Phase 1 results for its oral weight-loss drug, showing up to 5.3% weight loss in patients with minimal side effects. The company plans to launch the drug into Phase 2 trials later this year, following strong results from its injectable version. Analysts view the data as a "clear win" and believe the drug has best-in-class potential, positioning it to compete with current market leaders in the weight-loss drug space.